In COVID-19 patients-receiving ongoing immunomodulating/suppressive drugs, close monitoring of blood count changes, liver and kidney toxicity and, parameters such as IgG, IgM and CD4 T-cell numbers are justified [63]. This evidence concerns the gene CD40LG and COVID-19.